- Home
- OZ vs SERA Comparison
OZ vs SERA Comparison
Compare OZ & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- SERA
- Stock Information
- Founded
- OZ 2020
- SERA 2008
- Country
- OZ United States
- SERA United States
- Employees
- OZ N/A
- SERA N/A
- Industry
- OZ
- SERA Precision Instruments
- Sector
- OZ
- SERA Health Care
- Exchange
- OZ Nasdaq
- SERA Nasdaq
- Market Cap
- OZ 254.2M
- SERA 258.3M
- IPO Year
- OZ N/A
- SERA 2021
- Fundamental
- Price
- OZ $64.13
- SERA $6.73
- Analyst Decision
- OZ
- SERA
- Analyst Count
- OZ 0
- SERA 0
- Target Price
- OZ N/A
- SERA N/A
- AVG Volume (30 Days)
- OZ 4.6K
- SERA 135.2K
- Earning Date
- OZ 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- OZ N/A
- SERA N/A
- EPS Growth
- OZ N/A
- SERA N/A
- EPS
- OZ N/A
- SERA N/A
- Revenue
- OZ $1,700,000.00
- SERA $107,000.00
- Revenue This Year
- OZ N/A
- SERA N/A
- Revenue Next Year
- OZ N/A
- SERA $2,020.00
- P/E Ratio
- OZ N/A
- SERA N/A
- Revenue Growth
- OZ N/A
- SERA N/A
- 52 Week Low
- OZ $42.75
- SERA $1.56
- 52 Week High
- OZ $82.95
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- OZ 35.92
- SERA 39.99
- Support Level
- OZ $69.01
- SERA $6.87
- Resistance Level
- OZ $70.76
- SERA $7.27
- Average True Range (ATR)
- OZ 0.80
- SERA 0.50
- MACD
- OZ -0.74
- SERA -0.10
- Stochastic Oscillator
- OZ 0.00
- SERA 3.85
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.